Business Description
Viracta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92765F1084
Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.25 | |||||
| Equity-to-Asset | -0.3 | |||||
| Debt-to-Equity | -2.56 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -33.7 | |||||
| 3-Year EPS without NRI Growth Rate | -36.9 | |||||
| 3-Year FCF Growth Rate | -33.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 35.47 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.5 | |||||
| 9-Day RSI | 32.12 | |||||
| 14-Day RSI | 30.58 | |||||
| 3-1 Month Momentum % | 5.94 | |||||
| 6-1 Month Momentum % | -29.07 | |||||
| 12-1 Month Momentum % | -81.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.76 | |||||
| Quick Ratio | 0.76 | |||||
| Cash Ratio | 0.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 588.96 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -390.27 | |||||
| ROA % | -99.4 | |||||
| ROIC % | -214.18 | |||||
| 3-Year ROIIC % | -128.47 | |||||
| ROC (Joel Greenblatt) % | -11740.63 | |||||
| ROCE % | -361.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.08 | |||||
| EV-to-EBITDA | 0.08 | |||||
| EV-to-Forward-Revenue | 0.26 | |||||
| EV-to-FCF | 0.1 | |||||
| Earnings Yield (Greenblatt) % | 1250 | |||||
| FCF Yield % | -3840.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:VIRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viracta Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.1 | ||
| Beta | 0.13 | ||
| 3-Year Sharpe Ratio | -0.42 | ||
| 3-Year Sortino Ratio | -0.62 | ||
| Volatility % | 103.06 | ||
| 14-Day RSI | 30.58 | ||
| 14-Day ATR ($) | 0.016396 | ||
| 20-Day SMA ($) | 0.0384 | ||
| 12-1 Month Momentum % | -81.41 | ||
| 52-Week Range ($) | 0.008 - 1.31 | ||
| Shares Outstanding (Mil) | 39.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viracta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viracta Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Viracta Therapeutics Inc Frequently Asked Questions
What is Viracta Therapeutics Inc(VIRX)'s stock price today?
The current price of VIRX is $0.02. The 52 week high of VIRX is $1.31 and 52 week low is $0.01.
When is next earnings date of Viracta Therapeutics Inc(VIRX)?
The next earnings date of Viracta Therapeutics Inc(VIRX) is 2025-03-07 Est..
Does Viracta Therapeutics Inc(VIRX) pay dividends? If so, how much?
Viracta Therapeutics Inc(VIRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers